169 related articles for article (PubMed ID: 38534332)
1. Exploring Regorafenib Responsiveness and Uncovering Molecular Mechanisms in Recurrent Glioblastoma Tumors through Longitudinal In Vitro Sampling.
Morelli M; Lessi F; Franceschi S; Ferri G; Giacomarra M; Menicagli M; Gambacciani C; Pieri F; Pasqualetti F; Montemurro N; Aretini P; Santonocito OS; Di Stefano AL; Mazzanti CM
Cells; 2024 Mar; 13(6):. PubMed ID: 38534332
[TBL] [Abstract][Full Text] [Related]
2. The TNF receptor family member Fn14 is highly expressed in recurrent glioblastoma and in GBM patient-derived xenografts with acquired temozolomide resistance.
Hersh DS; Harder BG; Roos A; Peng S; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
Neuro Oncol; 2018 Sep; 20(10):1321-1330. PubMed ID: 29897522
[TBL] [Abstract][Full Text] [Related]
3. Tumor-Associated Microglia/Macrophages as a Predictor for Survival in Glioblastoma and Temozolomide-Induced Changes in CXCR2 Signaling with New Resistance Overcoming Strategy by Combination Therapy.
Urbantat RM; Jelgersma C; Brandenburg S; Nieminen-Kelhä M; Kremenetskaia I; Zollfrank J; Mueller S; Rubarth K; Koch A; Vajkoczy P; Acker G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681839
[TBL] [Abstract][Full Text] [Related]
4. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.
Lombardi G; De Salvo GL; Brandes AA; Eoli M; Rudà R; Faedi M; Lolli I; Pace A; Daniele B; Pasqualetti F; Rizzato S; Bellu L; Pambuku A; Farina M; Magni G; Indraccolo S; Gardiman MP; Soffietti R; Zagonel V
Lancet Oncol; 2019 Jan; 20(1):110-119. PubMed ID: 30522967
[TBL] [Abstract][Full Text] [Related]
5. Regorafenib Reverses Temozolomide-Induced CXCL12/CXCR4 Signaling and Triggers Apoptosis Mechanism in Glioblastoma.
Chiang IT; Liu YC; Liu HS; Ali AAA; Chou SY; Hsu TI; Hsu FT
Neurotherapeutics; 2022 Mar; 19(2):616-634. PubMed ID: 35267171
[TBL] [Abstract][Full Text] [Related]
6. Metabolic-imaging of human glioblastoma live tumors: A new precision-medicine approach to predict tumor treatment response early.
Morelli M; Lessi F; Barachini S; Liotti R; Montemurro N; Perrini P; Santonocito OS; Gambacciani C; Snuderl M; Pieri F; Aquila F; Farnesi A; Naccarato AG; Viacava P; Cardarelli F; Ferri G; Mulholland P; Ottaviani D; Paiar F; Liberti G; Pasqualetti F; Menicagli M; Aretini P; Signore G; Franceschi S; Mazzanti CM
Front Oncol; 2022; 12():969812. PubMed ID: 36132155
[TBL] [Abstract][Full Text] [Related]
7. Regorafenib in glioblastoma recurrence: A case report.
Detti B; Scoccianti S; Lucidi S; Maragna V; Teriaca MA; Ganovelli M; Desideri I; Lorenzetti V; Scoccimarro E; Greto D; Livi L
Cancer Treat Res Commun; 2021; 26():100263. PubMed ID: 33338858
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
9. Autophagy-based unconventional secretion of HMGB1 in glioblastoma promotes chemosensitivity to temozolomide through macrophage M1-like polarization.
Li Z; Fu WJ; Chen XQ; Wang S; Deng RS; Tang XP; Yang KD; Niu Q; Zhou H; Li QR; Lin Y; Liang M; Li SS; Ping YF; Liu XD; Bian XW; Yao XH
J Exp Clin Cancer Res; 2022 Feb; 41(1):74. PubMed ID: 35193644
[TBL] [Abstract][Full Text] [Related]
10. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells.
Zhao K; Schäfer A; Zhang Z; Elsässer K; Culmsee C; Zhong L; Pagenstecher A; Nimsky C; Bartsch JW
Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008590
[TBL] [Abstract][Full Text] [Related]
12. Influence of precedent drug on the subsequent therapy in the sequence of trifluridine/tipiracil with/out bevacizumab and regorafenib for unresectable or recurrent colorectal cancer.
Oshima K; Hirano H; Shoji H; Iwasa S; Okita N; Takashima A; Boku N
PLoS One; 2022; 17(6):e0269115. PubMed ID: 35653412
[TBL] [Abstract][Full Text] [Related]
13. CD73 as a target to improve temozolomide chemotherapy effect in glioblastoma preclinical model.
Azambuja JH; Schuh RS; Michels LR; Gelsleichter NE; Beckenkamp LR; Lenz GS; de Oliveira FH; Wink MR; Stefani MA; Battastini AMO; Teixeira HF; Braganhol E
Cancer Chemother Pharmacol; 2020 Jun; 85(6):1177-1182. PubMed ID: 32417936
[TBL] [Abstract][Full Text] [Related]
14. Gamma-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence.
Gilbert CA; Daou MC; Moser RP; Ross AH
Cancer Res; 2010 Sep; 70(17):6870-9. PubMed ID: 20736377
[TBL] [Abstract][Full Text] [Related]
15. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
He Y; Kaina B
Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
[TBL] [Abstract][Full Text] [Related]
16. Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I; Kleijn A; Ju J; Jimenez-Cowell K; Fabro F; Klein M; Chi Yen RT; Balvers RK; Li Y; Stubbs AP; Kers TV; Kros JM; Lawler SE; Beerepoot LV; Kremer A; Idbaih A; Verreault M; Byrne AT; O'Farrell AC; Connor K; Biswas A; Salvucci M; Prehn JHM; Lambrechts D; Dilcan G; Lodi F; Arijs I; van den Bent MJ; Dirven CMF; Leenstra S; ; Lamfers MLM
Br J Cancer; 2023 Oct; 129(8):1327-1338. PubMed ID: 37620410
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Perspective of Temozolomide Resistance in Glioblastoma Treatment.
Xia Q; Liu L; Li Y; Zhang P; Han D; Dong L
Cancer Invest; 2021 Sep; 39(8):627-644. PubMed ID: 34254870
[TBL] [Abstract][Full Text] [Related]
18. The Different Temozolomide Effects on Tumorigenesis Mechanisms of Pediatric Glioblastoma PBT24 and SF8628 Cell Tumor in CAM Model and on Cells In Vitro.
Damanskienė E; Balnytė I; Valančiūtė A; Alonso MM; Preikšaitis A; Stakišaitis D
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216113
[TBL] [Abstract][Full Text] [Related]
19. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma.
Lu C; Wei Y; Wang X; Zhang Z; Yin J; Li W; Chen L; Lyu X; Shi Z; Yan W; You Y
Mol Cancer; 2020 Feb; 19(1):28. PubMed ID: 32039732
[TBL] [Abstract][Full Text] [Related]
20. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial).
Lombardi G; Del Bianco P; Brandes AA; Eoli M; Rudà R; Ibrahim T; Lolli I; Rizzato S; Daniele B; Pace A; Pasqualetti F; Caccesse M; Bergo E; Magni G; De Salvo GL; Zagonel V
Eur J Cancer; 2021 Sep; 155():179-190. PubMed ID: 34388515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]